Free Trial
NASDAQ:ACRX

AcelRx Pharmaceuticals (ACRX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.49
$0.86
52-Week Range
N/A
Volume
243,500 shs
Average Volume
137,683 shs
Market Capitalization
$14.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.63

AcelRx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
∞ Upside
$4.63 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.40) to ($0.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.39 out of 5 stars

Medical Sector

710th out of 898 stocks

Pharmaceutical Preparations Industry

328th out of 429 stocks

ACRX stock logo

About AcelRx Pharmaceuticals Stock (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

ACRX Stock News Headlines

Musk Issues Urgent Warning…
Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.
Musk Issues Urgent Warning…
Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.
AcelRx CEO buys 10,000 shares
Positive Report for Acelrx (ACRX) from H.C. Wainwright
See More Headlines
Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
7/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACRX
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.63
High Stock Price Target
$5.00
Low Stock Price Target
$4.25
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$47.76 million
Pretax Margin
-3,711.25%

Debt

Sales & Book Value

Annual Sales
$1.77 million
Book Value
$2.65 per share

Miscellaneous

Free Float
16,443,000
Market Cap
$14.58 million
Optionable
Optionable
Beta
0.52
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

Key Executives

  • Mr. Vincent J. Angotti (Age 56)
    CEO & Director
    Comp: $906.54k
  • Dr. Pamela Pierce Palmer M.D. (Age 61)
    Ph.D., Co-Founder, Chief Medical Officer & Director
    Comp: $699.75k
  • Mr. Raffi Mark Asadorian (Age 55)
    Chief Financial Officer
    Comp: $637.5k
  • Mr. Anil N. Dasu (Age 61)
    Chief Engineering Officer
    Comp: $478.09k

ACRX Stock Analysis - Frequently Asked Questions

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) issued its earnings results on Monday, November, 15th. The specialty pharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($1.40). The specialty pharmaceutical company had revenue of $1.86 million for the quarter, compared to analysts' expectations of $1.20 million.

When did AcelRx Pharmaceuticals' stock split?

Shares of AcelRx Pharmaceuticals reverse split on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX) and OPKO Health (OPK).

This page (NASDAQ:ACRX) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners